Emergent BioSolutions Inc. EBS
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -9.56% | -29.89% | -28.81% | -29.91% | -22.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.56% | -29.89% | -28.81% | -29.91% | -22.74% |
| Cost of Revenue | -12.30% | -47.41% | -48.74% | -50.84% | -50.06% |
| Gross Profit | -6.70% | 10.90% | 18.09% | 26.94% | 80.27% |
| SG&A Expenses | -22.17% | -32.33% | -37.73% | -38.53% | -29.74% |
| Depreciation & Amortization | 1.84% | 0.15% | 0.00% | 0.15% | 0.15% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.12% | -40.32% | -42.83% | -44.91% | -42.26% |
| Operating Income | 18.28% | 288.89% | 326.36% | 257.36% | 172.56% |
| Income Before Tax | -176.56% | 105.62% | 157.94% | 162.37% | 132.99% |
| Income Tax Expenses | -39.84% | -82.54% | -36.69% | -23.08% | 475.28% |
| Earnings from Continuing Operations | -226.74% | 93.47% | 127.60% | 136.35% | 123.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -226.74% | 93.47% | 127.60% | 136.35% | 123.76% |
| EBIT | 18.28% | 288.89% | 326.36% | 257.36% | 172.56% |
| EBITDA | 6.45% | 157.79% | 271.68% | 660.68% | 504.01% |
| EPS Basic | -231.68% | 93.33% | 126.18% | 135.32% | 123.23% |
| Normalized Basic EPS | -0.35% | 125.36% | 147.90% | 150.33% | 136.85% |
| EPS Diluted | -244.96% | 89.71% | 122.42% | 131.63% | 121.77% |
| Normalized Diluted EPS | 1.46% | 117.08% | 140.57% | 144.09% | 134.22% |
| Average Basic Shares Outstanding | -3.15% | -1.21% | 0.99% | 2.96% | 3.55% |
| Average Diluted Shares Outstanding | -1.94% | -0.05% | 2.70% | 4.66% | 6.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |